FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
X

Find Clinical Drug Pipeline Developments & Deals by BioCorRx

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 22, 2020

            Details:

            In light of uncertainties across many industries due to COVID-19, BioCorRx wanted to reiterate that its pivotal GLP preclinical studies of BICX102, continue to progress and have been uninterrupted by COVID-19 to date.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institute on Drug Abuse

            Deal Size: $5.7 million Upfront Cash: Undisclosed

            Deal Type: Funding January 30, 2020

            Details:

            The grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). The grant is for the development of BICX102.